Skip to content Skip to sidebar Skip to footer

All Posts

HomeAll Posts
November 13, 2025

The Golden Arches That Never Close -( $MCD $SPY $DIA )

The opening bell rings as McDonald’s (MCD) steps onto the trading floor with the quiet confidence of a long-tenured heavyweight. This quarter isn’t a fireworks show; it’s a well-tuned engine: disciplined pricing, reliable traffic, and a franchise framework that stays resilient even when the macro weather turns gusty. The street reads the tape with the steadiness of a timeless thesis: durability beats novelty in markets that crave certainty.

Same-store sales and regional momentum

  • U.S. performance: U.S. same-store sales rose 2.4%, helped by value-oriented promotions and the relaunch of Snack Wraps alongside Extra Value Meals. This lane-change in pricing and promotions kept the check size up while foot traffic remained supportive in key pounds-for-pennies markets. The performance in the United States anchors the quarter’s narrative as a proof of the brand’s affordability story working in practice.​
  • Global footprint: Global comparable sales advanced 3.6%, signaling broad-based momentum across regions even as inflation cooled consumer budgets differently around the world. International markets contributed to a diversified growth thrust that reduces reliance on any single geography. Systemwide sales posted a solid expansion, underscoring the scale advantages that support steady cash generation.​
  • Regional nuance: International Operated Markets and International Developmental Licensed Markets grew in the mid-to-high single digits, translating to a broader base of revenue streams and a resilience buffer against localized pressures. This regional tilt matters for investors who model long-run margin resilience and unit growth as part of the core thesis.​

Margins and profitability

  • Consolidated revenues rose modestly, reflecting a mix of volume, pricing discipline, and cost management. The margin narrative remains anchored by operating efficiency and the lever of capital allocation—invest where returns are strongest while maintaining a steady cash flow profile. In the context of rising or volatile input costs, the ability to preserve operating income growth signals the strength of McDonald’s operating system.​
  • Operating income and earnings per share (EPS) showed positive momentum, supported by pricing power and a disciplined cost stance. The company also noted pre-tax charges tied to restructuring in some quarters, a factor investors weigh against the ongoing top-line growth story when assessing long-run profitability.​

Cash flow, capital allocation, and loyalty dynamics

  • Systemwide and loyalty-related metrics illustrate the depth of the brand’s reach: loyalty-member purchases contribute a meaningful share of the quarter’s revenue pool, signaling the effectiveness of marketing and loyalty promotions in sustaining buycycles. This dynamic matters for cash flow quality and for evaluating the durability of the company’s returns profile.​
  • Free cash flow and the pace of share repurchase or dividend activity continue to be a focal point for investors seeking steady yield and margin of safety in a market environment that prizes capital discipline. The quarter’s cash-generation strength reinforces McDonald’s reputation for prudent allocation over speculative expansion.​

Strategic takeaways and market sentiment

  • The quarter reinforces a durable thesis: McDonald’s can deliver value-oriented growth through a combination of menu innovation, value messaging, and international diversification, all while maintaining a steady, capital-light model for cash generation. In a market where headline risk can outsize fundamentals, the company’s track record of consistent performance and strategic agility remains a compelling narrative for patient capital.​
  • Going forward, investors will likely monitor the pace of global systemwide sales growth, any shifts in pricing strategy, and ongoing investments that affect throughput and margins. The balance of value for customers and efficiency for the enterprise will continue to define the stock’s risk-reward profile.​

The Sources

November 13, 2025

Risk-Off Rhythm & Volatility Returns: S&P 500 Slips as Tech Giants Weigh on the Tape – Nov. 13, 2025 -( $LLY $MCD $META $VIX Rise!)

Equities ended the session notably weaker after a volatile day characterized by renewed selling in tech and high-growth names. Major indices closed lower, with the Nasdaq Composite leading declines among the big three benchmarks. The day’s moves underscored a shift in risk sentiment as rate-cut expectations waver and investors digest policymakers’ signals about monetary policy in an uncertain growth environment. The markets ‘fear gauge’, the CBOE Volatility Index (VIX) popped up 14.22% to $20.00.

Key indices

  • S&P 500 (6,737.49, -1.66%): The broad equity gauge slid, reflecting broad-based pressure across sectors, especially momentum-driven groups. The close was decisively negative on the day, highlighting a risk-off tilt among investors seeking shelter in less volatile corners of the market.
  • Nasdaq Composite (22,879.36, -2.29%): Tech-focused index suffered the steepest drop as many of the megacap and high-valuation names faced selling pressure. The breadth of losses pointed to a rotation away from growth and into more traditional sectors or cash-equivalents.
  • Dow Jones Industrial Average (47,457.22, -1.65%): The Dow also traded lower but remained supported by durable, dividend-yielding names and select industrials. The decline in the Dow was pronounced but somewhat tempered by a handful of leadership stocks in other corners of the market.

Sector and stock notes

  • Technology and communication services bore the brunt of selling, consistent with a renewed focus on higher discount rates and slower earnings upgrades for growth-centric names. The weakness was broad rather than isolated to a few names, signaling a systemic reassessment of risk.
  • Broad-market leadership in recent sessions—often driven by megacaps—reversed, underscoring that the market is not simply chasing the latest momentum but weighing a potential pivot in the Fed trajectory and macro guidance.
  • Notable price action around legacy high-beta names and AI/semiconductor-related plays, which had previously been crowd favorites, reflected a shift in expectations about near-term catalysts and policy support.

Macro context

  • Traders continued to price in a slower pace of rate reductions, or even the risk of a delayed easing cycle, given ongoing economic data and Federal Reserve commentary. The result was a more cautious stance toward equities, particularly those with rich valuations or sensitivity to interest rates. The 2-yr treasury closed up at 3.603% as did the 10-yr at 4.126%.
  • The sentiment backdrop remained nuanced: while some pockets of the market still attract strategic buyers on pullbacks, the broader risk tolerance has yet to fully recover, pending clarity on inflation dynamics and rate path.

What this means for investors

  • A lower-risk posture may persist in the near term, with emphasis on high-quality, defensively oriented names and cash-like liquidity until macro signals become clearer.
  • For traders, swift, disciplined risk controls and clearly defined levels of entry and exit remain crucial, given the potential for continued volatility around policy expectations and macro data flows.

Tech Titans: AMD, NVIDIA, Broadcom, Intel, Oracle

  • AMD (AMD): Shares slid 4.2% to $247.96, retreating from recent highs as investors digested the company’s bullish AI-driven guidance and Q4 outlook. Despite robust revenue forecasts and a growing data center footprint, broader sector jitters and valuation concerns kept the rally in check. The market seems to be saying, “Show me the margin, not just the hype.”
  • NVIDIA (NVDA, $186.86, -3.58%): The chipmaker’s stock faced headwinds, joining the tech sell-off as rate-cut expectations cooled. While AI remains the golden goose, investors are now asking if the goose can keep laying eggs at the same pace.
  • Broadcom (AVGO, $339.98, -4.29%): The company’s recent foray into AI infrastructure continues to attract attention, though the sector’s volatility is a reminder that even the best diversification can’t fully insulate from a tech-wide correction.
  • Intel (INTC, $35.91, -5.23%): Intel’s shares were under pressure, reflecting ongoing challenges in the PC and semiconductor markets. The company’s turnaround efforts are still a work in progress, and investors remain skeptical about its ability to reclaim its former glory.
  • Oracle (ORCL): Oracle dropped 4.15% to $217.57, weighed down by sector-wide tech weakness. The company’s cloud and AI initiatives continue to be a bright spot, but the broader market’s risk-off mood has dimmed the shine for even the most established names.

Consumer & Industrial: Apple, Tesla, McDonald’s, Rio Tinto

  • Apple (AAPL): Apple’s stock followed the tech sector lower closing off .19% to $272.95 , with investors reassessing the company’s growth prospects amid a slowing global economy. The iPhone maker’s recent product launches have been well-received, but the market is now focused on the next big thing.
  • Tesla (TSLA): Tesla’s shares were volatile falling 6.64% to $401.99, reflecting the company’s ongoing challenges with production and competition. The stock’s wild swings are a reminder that in the EV market, the only constant is change.
  • McDonald’s (MCD): McDonald’s held up relatively well rising .21% to $307.58, with its defensive profile and steady cash flows providing a safe haven for investors. The company’s global footprint and brand strength continue to be a source of comfort in uncertain times.
  • Rio Tinto (RIO): Rio Tinto’s shares fell .10% to $71.04. The company’s diversified portfolio and strong balance sheet provide a buffer, but the sector’s fortunes are closely tied to global economic trends.

Communication & Software: Meta, Nokia, Palantir, Opendoor, OKLO

  • Meta (META): Meta’s stock rose +.14%, avoiding the broader tech sell-off. The company’s recent focus on AI and the metaverse continues to attract attention, but investors are now asking for more concrete results.
  • Nokia (NOK): Nokia’s shares fell 3.42% to $6.78, reflecting the company’s defensive profile and steady cash flows. The company’s focus on 5G and network infrastructure continues to be a source of strength.
  • Palantir (PLTR): Palantir’s stock was volatile falling 6.53% to $172.14, reflecting the company’s ongoing challenges with growth and profitability.
  • Opendoor (OPEN): Opendoor’s shares were under pressure falling 8.64% to $8.56 after yesterday’s double digit ascent, reflecting the ongoing challenges in the housing market. The company’s recent focus on technology and data analytics continues to attract attention, but the sector’s fortunes are closely tied to global economic trends,
  • OKLO (OKLO): OKLO’s stock fell 8.57% to $101.64

Health Care: Eli Lilly (LLY)

  • Eli Lilly (LLY): Eli Lilly’s stock toped $1k rising .50% to $,022.87 now up 32.50% YTD, driven by the company’s announcement of most-favored nation drug pricing for its weight-loss drugs. The move was well-received by investors, who see it as a sign of the company’s commitment to innovation and affordability.

Gold, Silver, and Bitcoin today


Gold: Closed at $4,157.50 per ounce, off .93%.
Silver: Silver fell 2.30% to $52.23/oz.​
Bitcoin: Fell below $100k down to the $8k range today off nearly 3%.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4795), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.34), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4690), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.40) and M2i Global, Inc. (MTWO, $.0958) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.92) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $34.01) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

  1. https://www.briefing.com/stock-market-update
  2. https://www.cnbc.com/2025/11/12/stock-market-today-live-updates.html
  3. https://www.reuters.com/business/us-futures-muted-traders-await-data-after-federal-reopen-2025-11-13/
  4. https://finance.yahoo.com/news/major-us-stock-indexes-fared-212100570.html
  5. https://www.bloomberg.com/news/articles/2025-11-12/stock-market-today-dow-s-p-live-updates
  6. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-13-2025
  7. https://www.businessinsider.com/stock-market-today-government-shutdown-tech-stocks-tsla-pltr-nvda-2025-11
  8. https://www.cnn.com/2025/11/13/economy/us-stock-market
  9. https://www.investopedia.com/dow-jones-today-11132025-11848610
  10. https://www.briefing.com/stock-market-update
  11. https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-sink-as-wall-street-eyes-fallout-from-us-shutdown-232101043.html
  12. https://www.briefing.com
  13. https://finance.yahoo.com/video/dow-nasdaq-p-500-fall-211447011.html
  14. https://www.briefing.com/weekly-wrap

November 13, 2025

Shutdown Ends: How Washington’s Budget Deal Reshapes Markets and Airlines -( $SPY $QQQ $DIA )

A brisk wind swept through the newsroom, carrying whispers of relief, risk, and the soft clack of keyboards. Screens flashed tickers as traders recalibrated after the shutdown’s end, a concrete event that shifted sentiment more decisively than a surprise rate cut. The narrative now orbits around effects: the immediate quiet on timing risk, the longer arc of policy execution, and the recalibration across sectors that depend on steady budgets.

The End of the Pause, The Start of the Pulse

Congress and the White House wrapped a short-term funding agreement around a longer-term budget framework, ending the shutdown and erasing the most acute near-term default scare. But endings in Washington rarely come with a clean slate. The real effects show up in project timelines reset, grant approvals resumed, and a disciplined push to reallocate funds toward previously stalled goals. Markets breathed a measured sigh, recognizing both relief and the work ahead to translate resolved headlines into resolved outcomes.

Sector Ripples: Airlines to Tech

Airlines pivoted from crisis mode to capacity planning, reworking load factors, fare curves, and staffing forecasts. The immediate disruption premium began unwinding as schedules stabilized and visibility returned to demand. In tech and defense, contractors and suppliers recalibrated pipelines, accounting for re-baselined budgets and new procurement rhythms. The banking and financial-services ecosystem absorbed the repricing of risk and the return-to-workflow in government-tied portfolios, adjusting liquidity forecasts and capital allocation plans accordingly.

The Policy Afterglow

With the crisis officially closed, agencies launched execution sprints: finalizing appropriations, syncing project timelines, and tightening crisis-response playbooks. The immediate market reaction cooled into a more durable, data-driven rhythm. Investors watched for evidence that the end-of-shutdown momentum translates into faster project execution, improved cash flows, and clearer forward guidance across sectors.

Editorial Tempo

The desk kept a brisk, precise tempo, translating policy cadence into actionable insight. The relief from resolution blended with a sober focus on implementation risk: will the budget framework unlock productivity, or will oversight and bureaucratic friction reintroduce headwinds? The narrative shifted from drama to delivery, from headlines to outcomes.

The Market-Choreography Throughline

Ending the shutdown altered the tempo, not the tune. The first-order effect was relief and clarity; the second-order effects depend on how quickly agencies convert appropriations into tangible results. Investors examined sector-specific catalysts: infrastructure funding ramps, defense modernization plans, healthcare and science funding, and the cadence of permit and grant approvals.

The Takeaway

The shutdown’s end marks a milestone, not a verdict on future fiscal discipline. Markets rewarded clarity but remain vigilant about execution risk, reform momentum, and the speed with which policy becomes practice.

November 12, 2025

Waymo on the Freeway: A Robotaxi Milestone rattles the markets


Waymo’s latest milestone—rolling driverless robotaxis onto U.S. freeways across select markets—reads like a sector earnings beat in real time. The move expands utilization horizons, tests risk-adjusted margins, and tightens the link between autonomous software reliability and fleet economics. Investors are watching how freeway deployments shift unit economics, insurance costs, and capex pacing as Waymo scales from controlled corridors to highway-grade operations. In a market where cost of capital and safety credentials dominate the narrative, this milestone reframes the roadmap for autonomous mobility as a capital-light, utilization-driven growth story.

Milestone in the making


Waymo’s highway rollout marks a decisive shift from limited-testing regimes to commercial highway operations. The change means more miles per vehicle per day, potentially improving fleet-operator economics even as the upfront costs for sensors, redundancy, and software safeguards remain high. The market will scrutinize maintenance cycles, software update cadence, and safety incident data as the levers that determine whether higher utilization translates into durable profitability or pressure on operating expenses. The broader arc includes regulatory navigation and the competitive dynamics with other autonomy developers, where speed to safe, scalable highway driving can become a meaningful differentiator.

Economic implications for investors

  • Fleet utilization and capex: Higher miles per vehicle can amortize fixed costs more quickly, but the drag of high-surity hardware and safety systems requires careful capital planning and amortization assumptions. Market pricing for robotaxi rides, insurance models, and maintenance will shape the long-run margin profile.
  • Insurance and risk management: Lower accident rates and advanced safety protocols can reduce premiums and claims costs over time, potentially unlocking favorable loss ratios as the software stack proves its reliability at scale.
  • Competitive landscape: Waymo’s execution on highways could set a de facto standard, influencing investor expectations for speed of deployment, regulatory approvals, and partnership opportunities in logistics and urban mobility ecosystems.
  • Revenue model evolution: The highway expansion could accelerate volume growth and open up new service variants, such as airport access, last-mile mobility bundles, and fleet-management software services for operators.

Operational and regulatory context


The highway-enabled service operates within a complex regulatory backdrop that includes state-by-state permitting, safety audits, and ongoing evaluations of risk in high-speed environments. Successful rollout requires not just technical reliability but disciplined execution around rider opt-ins, safety documentation, and incident reporting. Competitive differentiation will likely hinge on the robustness of the software stack, the depth of safety assurances, and the pace at which Waymo can extend highway access to additional markets without compromising the risk profile.

What this means for the future of mobility markets


If the freeway-capable robotaxi model proves scalable and profitable, broader mobility ecosystems could recalibrate investment priorities across AI software platforms, sensor suppliers, and autonomous-vehicle fleets. The potential spillovers into logistics, remote fleet monitoring, and insurance-linked services could broaden the addressable markets for AI-first mobility solutions. In short, the freeway milestone adds a tangible data point to a larger narrative: autonomous driving is moving from a laboratory experiment to a market-validated business model.

The Sources

  1. https://en.wikipedia.org/wiki/Waymo
  2. https://www.insurancejournal.com/news/national/2025/11/12/847254.htm
  3. https://teslanorth.com/2025/11/12/waymo-robotaxis-now-driving-on-freeways-and-to-airports/
  4. https://www.insurancejournal.com/news/west/2025/11/12/847243.htm
  5. https://www.ttnews.com/articles/waymo-robotaxis-freeways-first-us
  6. https://hoodline.com/2025/01/waymo-launches-testing-of-driverless-robotaxis-on-los-angeles-freeways-expanding-autonomous-reach/
  7. https://www.benzinga.com/news/25/11/48808971/waymo-launches-driverless-robotaxis-on-freeways-in-first-for-us-bloomberg
  8. https://en.wikipedia.org/wiki/Robotaxi
  9. https://www.azcentral.com/story/money/business/tech/2025/11/12/waymo-phoenix-freeways/87150109007/
November 12, 2025

DJIA Eclipses Record 48K As AMD & Opendoor Soar – Wed., Nov. 12, 2025 -( $AMD $EPRX $GOVX $INTC $MCD $NOK $NVDA $OKLO $OPEN $RIO $SOAR Rise!)

The major indices closed with a mixed tone after a session of careful balance between safety in value plays and the still-ambitious tilt toward growth. The S&P 500 eked out a gain, the Dow inched into positive territory as fresh macro cues rattled around, while the Nasdaq and Russell faced a modest pullback as investors recalibrated holdings in technology and growth names. The day’s price action underscored the ongoing tension between the resilience of the domestic economy and the wobble in high-duration tech multiples as traders digest inflation dynamics and central-bank chatter.

Macro and markets

  • S&P 500: Closed higher, up roughly 0.6% to 6,850.92, continuing a pattern of narrow daily ranges as investors weigh earnings signals against macro uncertainty. The index’s breadth remained modest, with leadership rotating between financials and select consumer-staples versus some laggards in high-growth tech.
  • Dow Jones Industrial Average: Finished in positive territory, registering a .68% gain to 48,254.82 and cresting the 48,000 level for the first time in today’s session’s intraday action. The cohort of bellwethers leaned toward industrials and select energy stocks amid inflation-watch narratives.
  • Nasdaq Composite and Russell indices: The Nasdaq retreated modestly off .26% to 23,406.46, pressured by a handful of heavyweight tech components whose softness outweighed pockets of strength elsewhere. The Russell 2000 also softened by .30% to 2,450.80, underscoring continued caution around mid- and small-cap risk assets amid higher-for-longer rate expectations.
  • Interest rates and yield curve: The yield environment remained influenced by ongoing expectations of the Federal Reserve’s policy path, with the 2-yr falling to 3.576% and the 10-yr falling to 4.069%.
  • Tariffs and trade: Today’s tariff chatter and policy signals kept market participants cautious about near-term import-position shifts, with some rotation into defensive sectors as a hedge against policy surprises.

Key corporate moves and notable names

  • AMD, NVIDIA, Intel (INTC, $37.89, +.03%): The semiconductor names remained in focus as investors weighed demand signals for GPUs and data-center accelerators against supply- and execution-related risk. NVIDIA’s (NVDA, $193.80, +.33%) and AMD’s (AMD, $258.89, +9%) momentum drivers remained tied to AI deployment cycles, enterprise demand, and any incremental guidance on production ramp and pricing discipline. Intel faced cautious positioning as investors awaited incremental semiconductor-capacity signaling and product progress updates.
  • Apple and Tesla: Apple’s ecosystem resilience and services growth continued to anchor the mega-cap narrative, while Tesla’s volatility persisted as the EV megatrend remains a focal point for both valuation and margin commentary. Both names drew attention to supply-chain normalization and demand in key geographies.
  • Broadcom (AVGO, $355.22, +.93%), Nokia ($7.02, +1.74%), McDonald’s (MCD, $306.94, +.04%), Oracle, Palantir, Meta, OKLO (OKLO, $111.17, +6.67%), Opendoor ($9.37, +10.50%), Rio Tinto Group (RIO, $71.11, +1.12%): Broadcom and Oracle continued to be barometers for enterprise technology demand and data infrastructure spend; Palantir and Meta rotated in and out of leadership groups as sentiment on AI exposure and online advertising cycles evolved. Nokia’s mobile/5G positioning faced competitive pressures. Rio Tinto and OKLO (nuclear-related) drew interest for sector-specific catalysts, while Opendoor’s housing-related equity trajectory remained sensitive to mortgage rates and housing demand. McDonald’s continued to reflect global consumer resilience in a mixed-cost environment, with currency effects and unit growth dynamics in focus.
  • Crypto and commodities: Gold ($4,202.40, +2.09%) and silver ($53.345, +5.13%) traded with a premium on risk-off sentiment in spurts, while oil fell 4.39% to $58.36 on global demand cues and inventory dynamics. Bitcoin pulled back ~.96% to $101,970.

What to watch next

  • FOMC and policy expectations: Markets continue to parse the timing and magnitude of potential rate adjustments, with investors awaiting any new summaries, dot plots, or communications from the Federal Reserve that could inform the next moves in the rate cycle and the tempo of balance-sheet normalization.
  • Inflation and macro data: Ongoing inflation data, labor market signals, and consumer demand indicators will be critical in shaping bets on timing for rate changes and the resilience of the earnings cycle across sectors, but the hopefully soon to tend U.S. shutdown is still delayingreports to be created.
  • Sector rotation drivers: Expect continued dispersion within technology versus value-oriented sectors, with AI-related demand, enterprise capex, and consumer demand remaining the principal determinants of near-term leadership in the indices.

Closing Macro Thought


In a market environment calibrated for the next policy signal and corporate earnings cadence, investors are favoring high-quality cash-generative franchises with clear secular tailwinds and pragmatic guidance. The day’s moves reflect a market that is discerning, not desperate, about growth winners while preserving capital in what remains a landscape of complexity and opportunity in equal measure.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4830), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.60, +1.07%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4979, +.38%), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR, $1.42, +2.90%) and M2i Global, Inc. (MTWO, 10, +8.58%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $4.02) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $37.) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

  1. https://finance.yahoo.com/news/stock-market-news-nov-12-144600218.html
  2. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-12-2025
  3. https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-circle-crcl-oklo/
  4. https://finance.yahoo.com/quote/%5EGSPC/history/
  5. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-11-2025
  6. https://archive.org/stream/InternationalHeraldTribune1969FranceEnglish/Nov%2016%201969,%20International%20Herald%20Tribune,%20%2335370,%20France%20(en)_djvu.txt
  7. https://www.reuters.com/world/china/global-markets-global-markets-2025-11-12/
  8. https://www.worldradiohistory.com/Archive-All-Music/Archive-RandR/2000s/2004/RR-2004-01-23.pdf
  9. https://www.financialjourney.com/campaigns/monthly-market-insights
  10. http://www.hongik-art.com/redboard/redboard.asp?tn=artinfo&key_id=1063&b_no=517&page=7&category=0&searchword=&orderby_1=No&orderby_2=Desc
  11. https://www.nasdaq.com/articles/house-vote-government-re-opening
  12. https://www.wsj.com/public/resources/documents/QWFbwbEWyywuj2tMgcsA-WSJNewsPaper-5-3-2025.pdf
  13. https://www.wsj.com/public/resources/documents/SskW9BECxkxudA2Y6ZCC-WSJNewsPaper-9-7-2024.pdf
  14. https://ufdcimages.uflib.ufl.edu/AA/00/06/85/31/01806/2024-08-04.pdf
  15. http://web.conradreynolds.com/trib/2019-05-22.pdf
  16. https://www.scribd.com/document/99078434/Times-Leader-07-04-2012
  17. https://www.egrouppartners.com/wp-content/uploads/2021/04/THE-BOOK-Complete-version.pdf
November 12, 2025

Can Centessa’s $250M Equity Windfall Transform Sleep Disorder Treatments? -( $CNTA $IBB $XBI )

Centessa Pharmaceuticals made waves in biotech finance this week by pricing its $250 million public offering at $21.50 per American Depositary Share (ADS)—a move that sent investors and industry watchers scrambling for their calculators and a fresh cup of clinical optimism.

Raising Capital: Wall Street Style

Centessa is issuing 11,627,907 ADSs, representing a healthy slice of its share pie, and even threw in a 30-day option for underwriters to pick up another 1,744,186 ADSs, just in case anyone arrived at the party late but still wanted dessert. The offering is slated to close around November 14, provided Wall Street’s usual litany of closing conditions don’t steal the show. Managing the syndicate are Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities—the investment banking equivalent of a red-carpet ensemble for any biotech bash.

Battle for Brainpower: Clinical Focus and Competition

All proceeds—after Wall Street shaves off its customary slice in fees and commissions—will be fueling Centessa’s ambitious plans to accelerate clinical trials in neurological disorders, especially its OX2R agonist program for narcolepsy and other sleep maladies. The company hopes this cash infusion, combined with a $349 million cash reserve, will keep the lights on and the pipettes working through mid-2027, a timeline that’s bold even for biotech standards. Just don’t mention net losses ($54.9 million for Q3)—in biotech, that’s less a scarlet letter and more like a badge of honor at the exploratory stage.

Investor Sentiment: Optimism With a Wink

Wall Street’s response: clear positive signals. Shares lifted following the announcement, proof investors are betting Centessa’s neuroscience pipeline might just redefine how the world sleeps, thinks, and perhaps dreams of future profits. Institutional investors, bolstered by top-tier underwriters, are signaling their confidence in Centessa like seasoned poker players who may have just glimpsed the ace in their hand. The deal’s structure also suggests management is keen to minimize “further dilution in the near term”—an attempt to keep loyal shareholders from seeing their stakes vanish like a dream before morning coffee.

Strategic Implications: Brains, Bucks, and Wit

Centessa’s move is more than just another biotech cash grab. It’s a strategic dance—aligning capital with critical scientific milestones, embracing risk, and balancing investor enthusiasm with the realities of regulatory mazes and competitive pressure from rivals like Alkermes and Takeda. As the company pursues registrational studies for its narcolepsy candidate, the street will watch closely to see if scientific promise can be translated into commercial reality and, in time, shareholder returns (or at least an interesting story for the next earnings call)..

In summary: Centessa’s $250 million public offering is a masterclass in biotech bravado, Wall Street showmanship, and scientific ambition—a tale fit for the front page, best paired with a strong espresso and a pinch of sophisticated humor.

The Sources

  1. https://finance.yahoo.com/news/centessa-pharmaceuticals-announces-pricing-250-014000007.html
  2. https://stocktitan.net/news/CNTA/centessa-pharmaceuticals-nasdaq-cnta-prices-250m-ads-offering-1163m-ads-o4bdwqinw8sl.html
  3. https://seekingalpha.com/news/4110845-centessa-pharmaceuticals-prices-250m-offering-at-usd21_5-per-ads-cnta-nasdaq
  4. https://www.investing.com/news/stock-market-news/centessa-prices-public-offering-of-116-million-adss-at-2150-each-3426054
  5. https://www.gurufocus.com/news/2490836/centessa-pharmaceuticals-cnta-launches-250m-public-offering
  6. https://www.marketscreener.com/quote/stock/CENTESSA-PHARMACEUTICALS-PLC-122366697/news/Centessa-Pharmaceuticals-Shares-Rise-After-Pricing-250-Million-American-Depositary-Share-Offering-45450435/
  7. https://www.nasdaq.com/articles/centessa-pharmaceuticals-prices-public-offering-at-$21.50-per-ads
  8. https://ainvest.com/centessa-pharmaceuticals-250m-equity-raise-strategic-capital
  9. https://www.quiverquant.com/news/CNTA/Centessa%20Pharmaceuticals%20plc%20Announces%20Underwritten%20Public%20Offering
  10. https://www.clinicaltrialsarena.com/analysis/narcolepsy-race-alkermes-ox2r-nt2-centessa/

November 12, 2025

Anthropic’s $50 Billion U.S. Data Center Bet: When AI Ambitions Meet Texas-Sized Infrastructure -( $MSFT $GOOG $NVDA $META )

In a move that could make even the most seasoned tech titans spill their morning espresso, AI startup Anthropic has announced plans to invest a head-turning $50 billion on custom-built data centers across the U.S.—with Texas and New York headlining this digital land rush. For a company younger than the latest iPhone model, breaking ground at this scale sounds less like business as usual and more like the digital equivalent of a rodeo—high stakes, a few bucking algorithms, and, presumably, very good insurance.

Building Claude’s Castle: Jobs, Joules, and Jargon

Anthropic’s ambitious buildout is expected to create not just AI bots, but real, old-fashioned American jobs—2,400 for construction and 800 permanent for wrangling the chips and wires once the dust settles. The company’s infrastructure partner Fluidstack will provide the “gigawatts of power capacity” needed to satisfy the insatiable AI workloads that can make an ordinary data center manager dream in kilowatt-hours. Anthropic CEO Dario Amodei says the project will help “accelerate scientific discovery and solve complex global challenges,” which, in tech-PR language, loosely translates to “We need bigger servers and want to hire your cousin Mel from Austin.”

The Great American AI Arms Race

Anthropic’s plan joins a stampede of data center mega-projects announced this year, as the firm lines up alongside OpenAI, Meta, Google, Microsoft, and Nvidia—all armed with their own colossal budgets and future-forward bravado. OpenAI leading a $500 billion initiative, Meta going all-in with a 2-gigawatt Louisiana data center, and Zuckerberg promising to spend $600 billion—suddenly, what counted as “a lot of money” last week seems quaint.

Cloud Wars and Skeptical Investors

Of course, all this bullishness has prompted some sober Wall Street desk analysts to wonder whether the future of AI is more bubble than boom. While Anthropic’s Claude chatbot earns praise for its safety-first features and transparency—trendy virtues in today’s algorithmic wild west—profit margins remain elusive even as business adoption grows. Still, with Anthropic recently closing a $13 billion funding round at a $183 billion valuation, the company’s message to the market is clear: infrastructure is the new innovation, and whoever owns the hardware may well own the future.

From Server Farms to Silicon Frontiers

As the first sites are expected to go live in 2026, Anthropic’s investment signals a shift in the AI race—from breakthroughs in neural networks to who can build the biggest, most efficient digital fortresses. If all goes to plan, Texas and New York might soon be known not only for brisket and bagels, but for the clusters of relentless Claude models plotting world peace (or at least, your next PowerPoint).

The Sources

  1. https://www.cnbc.com/2025/11/12/anthropic-ai-data-centers-texas-new-york.html
  2. https://finance.yahoo.com/news/anthropic-to-spend-50-billion-on-us-data-center-buildout-155605972.html
  3. https://www.reuters.com/technology/anthropic-invest-50-billion-build-data-centers-us-2025-11-12/
  4. https://www.anthropic.com/news/anthropic-invests-50-billion-in-american-ai-infrastructure
  5. https://www.tradealgo.com/news/anthropics-invests-50-billion-in-us-based-ai-data-centers
  6. https://www.businessinsider.com/anthropic-50-million-investment-ai-infrastructure-data-centers-2025-11
  7. https://wtop.com/national/2025/11/anthropic-announces-50b-investment-in-new-us-data-centers-to-meet-ai-demand/
  8. https://www.youtube.com/watch?v=chRjXUdMS_w
  9. https://www.anthropic.com/news/expanding-our-use-of-google-cloud-tpus-and-services
  10. https://finance.yahoo.com/video/anthropic-spend-50-billion-build-151705727.html
  11. https://www.bloomberg.com/news/articles/2025-11-12/anthropic-commits-50-billion-to-build-ai-data-centers-in-the-us
  12. https://techcrunch.com/2025/11/12/anthropic-announces-50-billion-data-center-plan/
  13. https://www.wired.com/story/data-center-ai-boom-us-economy-jobs/
  14. https://www.googlecloudpresscorner.com/2025-10-23-Anthropic-to-Expand-Use-of-Google-Cloud-TPUs-and-Services
  15. https://www.usnews.com/news/best-states/california/articles/2025-11-12/anthropic-announces-50b-investment-in-new-us-data-centers-to-meet-ai-demand
  16. https://cloudwars.com/ai/anthropic-taps-over-a-gigawatt-of-google-cloud-tpus-to-power-next-gen-claude-models/
  17. https://www.salesforce.com/news/press-releases/2025/10/14/anthropic-regulated-industries-partnership-expansion-announcement/
  18. https://www.anthropic.com/news
  19. https://www.reddit.com/r/stocks/comments/1ov8c7g/anthropic_to_spend_50_billion_on_us_ai/
November 12, 2025

AMD Eyes $1 Trillion Data Center Chip Market With Aggressive Growth Plan -( $AMD $NVDA $SPY )

Advanced Micro Devices (AMD) is setting the stage for a robust resurgence in the data center arena, projecting a 60% jump in revenue over the next three to five years. This forecast, unveiled at the company’s recent Financial Analyst Day, underscores AMD’s aggressive push into AI and data center markets, challenging the industry titan Nvidia (NVDA) for dominance. With 2025 data center revenues already hitting $16 billion, the chipmaker is betting on a compound annual growth rate (CAGR) that will have Wall Street taking notice and investors eyeing a potential treasure trove.

Chasing Growth: The AI Factor

Led by CEO Lisa Su’s unwavering confidence, AMD expects to maintain a broad company-level revenue growth averaging above 35% annually, backed by non-GAAP operating margins exceeding 35% and earnings per share forecasted to surpass $20. The data center segment, powered by innovations such as the 5th Gen EPYC processors and AMD Instinct MI350 GPUs, is anticipated to grow even faster than the rest of the business, reflecting surging demand for AI chips and cloud infrastructure. In fact, the AI chip demand is considered insatiable—just the kind of appetite tech execs dream about when optimizing quarterly earnings calls.

The optimistic outlook extends beyond data centers. AMD sees a consistent upward trajectory in its embedded, client, and gaming divisions, with revenue growth expected to cross double digits, albeit more modestly than the superstar data center segment. The firm’s fourth-quarter 2025 guidance includes revenues around $9.6 billion, illustrating healthy momentum, while the company carefully sidesteps risks associated with regulatory approvals like shipments of its Instinct MI308 GPUs to China.

Investors Take Note: The Financials

Investors are responding with enthusiasm, lifting AMD’s stock despite the crowded battlefield with Nvidia, whose market capitalization still dwarfs AMD’s but faces mounting competitive heat. Industry analysts estimate that by 2030, the data center chip market could balloon to a staggering $1 trillion, with AMD positioned as a key beneficiary of this expansion. The chipmaker’s narrative today reads like a classic David versus Goliath story, with sophisticated silicon instead of slingshots, and a strategy grounded in innovation, scalability, and a pinch of Wall Street-showroom charm.

The Road Ahead

As AMD journeys toward its ambitious goals, it walks a fine line between explosive growth and the tech sector’s ever-present volatility. Yet, if these forecasts hold, the company won’t just be making chips—it will be making history. And in Silicon Valley, as anywhere else, that’s the best kind of market cap one can ask for.

The Sources…

  1. https://ir.amd.com/news-events/press-releases/detail/1266/amd-unveils-strategy-to-lead-the-1-trillion-compute-market-and-accelerate-next-phase-of-growth
  2. https://finance.yahoo.com/news/amd-says-its-data-center-revenue-will-jump-60-over-the-next-3-to-5-years-234017711.html
  3. https://www.reuters.com/business/amd-expected-outline-plans-ai-chip-business-analyst-day-2025-11-11/
  4. https://ir.amd.com/news-events/press-releases/detail/1265/amd-reports-third-quarter-2025-financial-results
  5. https://www.bloomberg.com/news/articles/2025-11-11/amd-predicts-accelerating-sales-growth-driven-by-data-centers
  6. https://www.cnbc.com/2025/11/11/amd-lisa-su-growth-ai-analyst-day.html
  7. https://www.perplexity.ai/finance/AMD
  8. https://www.trendforce.com/news/2025/11/12/news-amds-ai-chips-power-data-center-revenue-100b-expected-in-5-years-with-60-cagr/
  9. https://finance.yahoo.com/news/amd-expected-outline-plans-ai-110215978.html
  10. https://finance.yahoo.com/news/bank-america-revamps-amd-stock-213300323.html
  11. https://www.linkedin.com/news/story/amd-targets-35-annual-sales-growth-as-ai-demand-soars-6754508/
  12. https://www.investing.com/news/stock-market-news/amd-expected-to-outline-plans-for-ai-chip-business-at-analyst-day-4348696
  13. https://ir.amd.com/news-events/press-releases/detail/1257/amd-reports-second-quarter-2025-financial-results
  14. https://mlq.ai/news/amd-projects-35-annual-revenue-growth-driven-by-ai-and-data-center-expansion/
  15. https://www.facebook.com/Reuters/posts/amd-expects-data-center-market-to-grow-to-1-trillion-by-2030click-the-link-in-th/1387495049907890/
  16. https://www.barrons.com/articles/amd-stock-price-analyst-day-today-46dcc700
  17. https://www.thestreet.com/investing/stocks/bank-of-america-revamps-amd-stock-forecast-before-key-event
  18. https://finance.yahoo.com/news/prediction-amd-stock-soar-over-131100100.html
  19. https://www.datacenterdynamics.com/en/news/amd-posts-record-data-center-revenue-for-q3-2025-as-compute-demand-shows-no-signs-of-slowing/
  20. https://finance.yahoo.com/news/amd-stock-reach-300-2025-130002285.html
  21. https://www.cnn.com/markets/stocks/AMD
November 11, 2025

Daily Stock Highlights: Dow’s Record Run, S&P Gains, Nasdaq Dips, Plus Lilly, Tesla, Nvidia -( $AAPl $DIA $EPRX $LLY $MCD $MTWO $OPEN $SER $SPY Rise!)

In honor of Veterans Day, the market brought both rally and resilience, as portfolio generals weighed AI ambition against time-honored value plays. Whether saluting S&P records or commiserating with Nasdaq laggards, investors marched onward—sometimes in formation, sometimes in hopeful disorder, and always looking for the next bullish bugle. Indeed, Wall Street marked Veterans Day with a decidedly mixed salute to risk-taking—some blue chips boosted their berets, while the tech-heavy Nasdaq tripped over its shoelaces. Investors digested headline macro reports and more than a few market plot twists: from Nvidia’s sudden swoon to Tesla’s compensation fireworks. Here’s the market’s parade review—for posterity, profit, and just a dash of sophisticated humor.

Index Performances

The S&P 500 rallied 1.5% to close at 6,846.81, +.21% with eight of its eleven broad sectors saluting in the green after falling to 6,807.58 in the early going. The Dow Jones flexed its muscle, surging more than 500 points to a record close at 47,927.96, +1.18% and the Russell 2000 joined the festivities with a modest rise closing at 2,458.28,+.11% after dropping early. However, the Nasdaq tripped on its own AI ambitions, dragged lower by Nvidia’s stumble and profit-taking across tech’s usual suspects and closed at 23,468.30,-.25%.

Macroeconomic Data and Reports

Today’s calendar featured the ADP jobs data signaling a softer labor market—a notion that sent economists into a coffee-fueled huddle. The jobless claims 4-week average nudged down to 249,000, slightly below previous readings, while the Monthly Budget Statement revealed a robust $198 billion surplus, providing policymakers with a post-shutdown fiscal cushion.

Notable Company News & Stock Performances

  • Eli Lilly (LLY): Shares closed up another 2.27% at $988.62 following bullish R&D expansions in diabetes and oncology, strengthened by partnerships scaling up obesity medicine access and embracing AI-powered therapy development.
  • Nvidia: The chipmaker sank 2.96% to $193.16 after SoftBank disclosed a full exit, briefly chilling Wall Street’s recent obsession with all things silicon-driven. Despite this, Nvidia maintains a “Strong Buy” consensus among analysts looking past today’s noise to future dominance.
  • Apple (AAPL): Displayed textbook restraint in AI spending, outperforming peers as a port in the tech storm closing at $275.25, +2.16%. Its shares rose, the biggest point-gainer in the S&P today, with investors favoring its cash-rich, stress-free approach.
  • Tesla (TSLA): Closed down 1.26% at $439.62.
  • Broadcom (AVGO): Shares fell 1.79% to $351.96 after recently being propelled by its AI infrastructure pivot and blockbuster OpenAI collaboration, with earnings anticipated to provide further fireworks.
  • Meta: The social media titan stabilized at $627.08,-.74% after last month’s steep post-earnings tumble, as investors recalibrated their faith in Mark Zuckerberg’s Metaverse ambitions.
  • Nokia, McDonald’s (MCD, $306.83, +2.58%), Rio Tinto (RIO, $70.32,+.04%), Oracle, Intel, OKLO, Opendoor (OPEN, $8.48, +6.40%), Palantir Technologies: News flow was lighter today, but these names rode the broad equity tide with movements mostly in line with their sectors. Notably, McDonald’s.

Tariffs, FOMC, Yield Curve, and Rates

No new tariff salvos were fired today; investors remain on edge for future global chess moves. The yield curve held steady following the Senate’s shutdown-ending vote, with rates market watching for clues on the next Fed move. The 10-yr is at 4.121% and the 2-yr is at 3.601%. The Federal Reserve’s foggy data backdrop—thanks to government shutdown interruptions—means rate cuts for December are no longer a “foregone conclusion”; the next FOMC meeting is slated for December 9-10, with uncertainty as its co-host.

Commodities and Cryptocurrency Prices

  • Gold and Silver: Both metals shimmered, with gold holding just below $4,135.60/oz and silver showing strength as geopolitical risks percolated closing at $51.065/oz.
  • Oil: Prices rose 1.41% to $60.98/bbl rising on Russia sanctions.
  • Bitcoin: Fell sharply ~3% to the ~$103k level.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4896), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.53, +4.82%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4960), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR, $1.38) and M2i Global, Inc. (MTWO, 10, +8.58%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $4.08, +2.26%) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $37.22, +.92%) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

  1. https://www.bloomberg.com/news/articles/2025-11-10/stock-market-today-dow-s-p-live-updates
  2. https://finance.yahoo.com/news/live/stock-market-today-dow-jumps-over-500-points-to-record-close-nvidias-slide-drags-on-nasdaq-210017301.html
  3. https://finance.yahoo.com/news/stock-market-news-nov-11-142200075.html
  4. https://www.barrons.com/livecoverage/stock-market-news-today-111125
  5. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-11-2025
  6. https://www.latimes.com/business/story/2025-11-11/shutdown-leaves-a-mark-on-an-already-struggling-economy-from-lost-paychecks-to-canceled-flights
  7. https://tradingeconomics.com/united-states/calendar
  8. https://www.ainvest.com/news/eli-lilly-shares-surge-4-54-strategic-shift-fuels-healthcare-optimism-2511/
  9. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/eli-lilly-lly-is-up-78-after-expanding-access-and-partnershi
  10. https://247wallst.com/forecasts/2025/11/11/nvidia-nvda-price-prediction-and-forecast/
  11. https://www.cnbc.com/2025/11/11/analysts-call-this-lagging-stock-a-buy-plus-whats-behind-nvidias-decline.html
  12. https://fortune.com/2025/11/11/wall-street-artifical-intelligence-nvidia-chip-stocks-technology-investors-coreweave-paramount-skydance/
  13. https://www.latimes.com/business/story/2025-11-11/apples-restraint-finds-fans-as-ai-spending-faces-scrutiny
  14. https://polymarket.com/event/aapl-up-or-down-on-november-11-2025
  15. https://www.investopedia.com/tesla-stock-is-slipping-today-as-investors-eye-chinese-sales-numbers-11847299
  16. https://www.ainvest.com/news/tesla-shares-soar-3-66-landmark-1t-compensation-vote-elon-musk-riding-ai-robotics-ambitions-2511/
  17. https://www.barchart.com/story/news/36019876/what-are-wall-street-analysts-target-price-for-broadcom-stock
  18. https://247wallst.com/investing/2025/11/09/why-meta-is-the-stock-to-watch-this-earnings-season/
  19. https://247wallst.com/investing/2025/11/11/stock-market-live-november-11-sp-500-voo-hits-pause-on-shutdown-end-rally/
  20. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-10-2025
November 11, 2025

Palantir’s $500B Bet: How Alex Karp’s Anti-Playbook Rewrote the AI Rulebook -( $PLTR $SPY $DIA $QQQ )

Palantir Technologies’ (PLTR) peculiar rise, led by philosopher-CEO Alex Karp, looks less like a traditional Silicon Valley success story and more like avant-garde theater—if the tickets sold out and the popcorn dividends paid venture-style returns. Record-breaking earnings now find Palantir hovering around a $500 billion market cap, boosting Karp’s argument that the “anti-playbook” ethos is more than high-minded rhetoric: it’s a bottom-line bonanza for America’s unlikely samurai software shop.

Startup Vibe at Scale

Strolling the Palantir office, a world where creative chaos meets the discipline of the battlefield, feels a bit like crashing a startup reunion hosted inside the Pentagon—big scale, ISO certifications, and zero patience for “conventional analysts” wearing consensus like a badge. “We gave venture-style returns to retail investors and private-equity outcomes to enterprise clients,” Karp crowed, fresh off earnings that turned Wall Street analysts into a kind of voluntary Greek chorus of skeptics.

Beyond Software: Bias and Moral Conviction

Karp’s flat organizational model means artistic impulses can override the staid, rational calculus that governs most SaaS empires. Palantir’s AIP, now called the “operating system for the AI era,” compresses sales cycles and gives clients what they ought to ask for, not merely what’s on their spec sheet—a tactic that seems both deeply philosophical and suspiciously lucrative. Clients sometimes “don’t like these guys,” but as one industrial exec reportedly put it: “When you bring someone home safely, they learn to love you,” even if the onboarding is faster than eating a cupcake at a Berlin gallery opening.

Dyslexia and the Art of Nonconformity

Karp credits lifelong dyslexia—a condition that vetoes playbooks and incentivizes originality—as key to his management method. This approach, “delivering intuition over hierarchy,” gives Palantir a kind of corporate anti-aging serum: twenty years old and still “freakishly young” at heart. In the interview, he makes the case for meritocracy, realism, and American values—a palette borrowed, perhaps, from family lore about artists and textile traders, now repurposed to outmaneuver adversaries at home and abroad.

AI as the Great Equalizer

Despite sequined skepticism about the AI boom, Palantir refuses to sell “parasitic products” that addict customers to mediocrity. Instead, AIP orchestrates supply chains and defense assets, helping commanders predict adversary moves and, in Karp’s words, “prevent war” rather than merely wage it. The software, which claims to grant near-omniscient situational awareness, isn’t just a feature—it’s moral conviction on the cloud.

Humor in the Hallways

Karp’s aversion to cupcakes (“I don’t want to be a cupcake because I don’t want to get eaten”) reveals a rare, dry humor in a CEO who otherwise dances on the fault lines of U.S. policy, immigrant rights, and global alliances. Employee folklore abounds: no one has time for hierarchy, and if Karp shows up at your desk, the only question is, “Are you adding GDP?”.youtube​

Wall Street’s Uncomfortable Crush

Palantir’s numbers—63% year-over-year revenue growth to nearly $1.2 billion—earned it new respect and fresh controversy. In the era of AI-drenched hype, Karp’s insistence on value creation over showmanship looks prescient, if not exactly comforting for the average short seller. Critics question the sustainability and the audacity of Palantir’s government contracts—sometimes for deeply political reasons—but Karp invites detractors to “judge us by our enemies,” adding a touch of gladiatorial bravado to the financial press call.

The Takeaway

Palantir’s “anti-playbook” formula might be hard to replicate, but as Karp puts it, “You want to sleep at night? Make sure your adversary knows they are going to get totally—effed up—if they screw with us.” One imagines the company’s next earnings call as half board meeting, half philosophical salon, full of iced cupcakes no one dares ea.

The Sources…

  1. https://seekingalpha.com/article/4841783-palantir-stellar-execution-but-valuation-is-simply-too-high
  2. https://www.denvergazette.com/2025/11/04/denver-based-palantir-saw-record-earnings-but-ai-bubble-fears-hit-stock/
  3. https://www.investopedia.com/palantir-ceo-says-the-software-maker-is-seeing-otherworldly-growth-driven-by-ai-demand-11842478
  4. https://investors.palantir.com/news-details/2025/Palantir-Reports-Q3-2025-U-S–Comm-Revenue-Growth-of-121-YY-and-Revenue-Growth-of-63-YY-Guides-Q4-Revenue-to-61-YY-and-U-S–Comm-Revenue-to-121-YY-Raises-FY-2025-Revenue-Guidance-to-53-YY-Crushing-Consensus-Expectations/
  5. https://www.youtube.com/watch?v=RG9fdLzxTaw
  6. https://www.barrons.com/articles/palantir-ai-earnings-microsoft-alex-karp-a0c872d8
  7. https://stocktwits.com/news-articles/markets/equity/alex-karp-most-important-thing-palantir-does-prevent-wars/cL2vDYRRETo
  8. https://www.webpronews.com/alex-karp-overcoming-dyslexia-to-build-palantirs-ai-empire/
  9. https://finance.yahoo.com/news/why-palantir-technologies-pltr-shares-173601164.html
  10. https://www.businessinsider.com/palantir-ceo-alex-karp-calls-company-anti-woke-revenue-surge-2025-11
  11. https://www.wired.com/story/alex-karp-goes-to-war-palantir-big-interview/
  12. https://www.reuters.com/technology/palantir-forecasts-fourth-quarter-revenue-above-estimates-solid-ai-demand-2025-11-03/
  13. https://finance.yahoo.com/news/could-palantir-best-ai-stock-101500865.html
  14. https://www.theglobeandmail.com/investing/markets/stocks/PLTR/pressreleases/36041555/down-11-is-palantir-a-buy-on-the-dip/
  15. https://www.aol.com/articles/palantir-stock-buy-103500324.html
  16. https://www.morningstar.com/news/marketwatch/20251103368/palantirs-stock-falls-despite-ai-fueling-another-flurry-of-records
  17. https://en.wikipedia.org/wiki/Alex_Karp
  18. https://www.youtube.com/watch?v=wWxWTfjTR5A
  19. https://www.linkedin.com/posts/jacoogan_palantir-technologies-ceo-alex-karps-advice-activity-7369774085112782848-tYcv
  20. https://www.cnbc.com/video/2025/11/07/watch-cnbcs-full-interview-with-palantir-ceo-alex-karp-in-pebble-beach.html
Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here

Copyright © 2026 Vista Partners, LLC. All rights reserved